Sign in
Back
Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate
Journal article   Peer reviewed

Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate

Aamer Aleem and Neelam Siddiqui
Leukemia & lymphoma, Vol.46(7), pp.1097-1099
01/07/2005
DOI: https://doi.org/10.1080/10428190500096781
PMID: 16019565

Abstract

Antineoplastic Agents - therapeutic use Ascites - diagnosis Ascites - drug therapy Ascites - etiology Benzamides Blast Crisis - genetics Cytogenetic Analysis Fusion Proteins, bcr-abl - genetics Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Middle Aged Piperazines - therapeutic use Pyrimidines - therapeutic use Remission Induction
Patients with chronic myeloid leukemia (CML) can develop extramedullary involvement during the course of the illness. This usually occurs during the accelerated phase or blast crisis. We describe a patient who presented with massive ascites probably due to mesenteric/peritoneal infiltration during chronic phase CML. There was an excellent response to imatinib with a complete cytogenetic response and total disappearance of ascites.

Metrics

1 Record Views

Details